About Us

Improve human health with innovation

BJ Bioscience Inc.

BJ Bioscience Inc. is a clinical stage biotechnology company dedicated to research and development of innovative drugs for unmet medical needs worldwide. It is founded by experts with many years of experience in research and development of innovative drugs and complementary expertise, including a review expert of National Key Innovative Drug R&D Projects, the National Health Commission of China. Based on its top-notch BJ-SIB bispecific antibody platform and trade secret protected antibody generation and screening technology, BJ Bioscience focuses its R&D on oncology, infectious and autoimmune diseases. Key members of the company's R&D team have many years of experience in R&D and management of antibody drugs from key national scientific research institutions, domestic and foreign pharmaceutical companies especially European and American multinational companies

With a global perspective of its R&D and strong capital support, BJ Bioscience has a global presence from the beginning of its inception, with R&D laboratories in both San Francisco, USA and Shanghai, China. Such global perspective and presence enables the company to realize globally the full range of talents, technology, management and capital market in the early stage of its entrepreneurship and lays a solid foundation for its global positioning and development. 

Vision

Healthier body and happier life through innovation

Mission

Based on our top-notch BJ-SIB bispecific antibody platform and trade secret protected antibody generation and screening technology, we are committed to research and development of innovative biopharmaceuticals for the treatment of immune-related diseases with a focus on cancer, autoimmune diseases and infectious diseases worldwide

Cause

Provide patients with innovative and high-quality biopharmaceuticals

Founders and Management Team

  • Joe Zhang PhD. MD. DABT

    Co-founder and CEO

  • John Wang PhD

    Co-founder and CSO

  • Leijun Hu PhD

    SVP of Translational Medicine

Our History

  • 2018

    Official operation of the company

  • 2019

    The first IND was approved by the US FDA

    CMAB Biopharma and BJ Bioscience Inc. have established comprehensive strategic cooperation

    The first patient completed the first dose of Phase 1 clinical trial in the United States 

  • 2021

    The IND of the company's second project was approved by the U.S. FDA

    The dual antibody project based on the company's BJ-SIB® dual antibody platform entered the pilot-scale production

  • 2022

    Shanghai Zhangjiang R&D Center is established

  • 2018

    Official operation of the company

  • 2019

    The first IND was approved by the US FDA

    CMAB Biopharma and BJ Bioscience Inc. have established comprehensive strategic cooperation

    The first patient completed the first dose of Phase 1 clinical trial in the United States 

    •  
  • 2021

    The IND of the company's second project was approved by the U.S. FDA

    The dual antibody project based on the company's BJ-SIB® dual antibody platform entered the pilot-scale production

  • 2022

    Shanghai Zhangjiang R&D Center is established

  • 1

    2018

  • 2

    2019

  • 5

    2021

  • 2

    2022

  • 1

    2018

  • 1

    2019

  • 1

    2021

  • 1

    2022